Celcuity

Celcuity Change in Working Capital

The Change in Working Capital of Celcuity (CELC) as of Nov 11, 2026 is -2.65 M USD. In the previous year, Change in Working Capital was 18.35 M USD — a change of -114.45% (lower).

Change in Working Capital

-2.65 MUSD

YoY

-114.45%

Last updated:

Change in Working Capital of Celcuity is 2025 -2.65 M USD. Change in Working Capital of Celcuity was 2024 18.35 M USD. It decreases by -114.45% lower compared to the previous year.

The Celcuity Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-73,431.00 USD
Jan 1, 2019
-62,239.00 USD
Jan 1, 2020
179,016.00 USD
Jan 1, 2021
819,811.00 USD
Jan 1, 2022
-1.19 M USD
Jan 1, 2023
3.86 M USD
Jan 1, 2024
18.35 M USD
Jan 1, 2025
-2.65 M USD
The Celcuity Change in Working Capital history
YEARChange in Working CapitalYoY
-2.65 MUSD-114.45%
18.35 MUSD+375.44%
3.86 MUSD-423.80%
-1.19 MUSD-245.39%
819,811.00USD+357.95%
179,016.00USD-387.63%
-62,239.00USD-15.24%
-73,431.00USD-27.94%
-101,909.00USD-163.00%
161,755.00USD-3.65%
167,879.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Change in Working Capital of Celcuity is -2.65 M USD in 2025.

Change in Working Capital of Celcuity changed from 18.35 M USD to -2.65 M USD, representing a -114.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Celcuity since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Celcuity

All Key Metrics — Celcuity